Sarcoma - oncology - SA Health Approved Cancer Chemotherapy Protocol Register

Soft tissue sarcoma

Soft Tissue Sarcoma
Protocol Administration at chemotherapy unit level Review Date
Angiosarcoma locally advanced or metastatic PACLItaxel Medium August 2023
Soft Tissue Sarcoma Dacarbazine – Interim Protocol.
For information on this protocol please contact the SA Health Cancer Drug Committee.
Medium August 2021
Liposarcoma advanced or metastatic eribulin Medium August 2023
Soft tissue sarcoma advanced pazopanib Low August 2023
Soft tissue sarcoma advanced or metastatic trabectedin3 Medium August 2023
Soft tissue sarcoma locally advanced or metastatic DOXOrubicin Medium August 2023
Soft tissue sarcoma locally advanced or metastatic DOXOrubicin and IFOSFamide Medium August 2023

Bone sarcoma

Bone Sarcoma
Protocol Administration at chemotherapy unit level Review Date
Ewing sarcoma recurrent or metastatic irinotecan and temozolomide Medium August 2023
Ewing sarcoma IE (iFOSFamide and etoposide) (part 2 of VDC/IE) High August 2023
Ewing sarcoma VAC (vinCRISTine daCTINomycin CYCLOPHOSPHamide) (part 2a of VIDE followed by VAC or VAI) High August 2023
Ewing sarcoma VAI (vinCRISTine daCTINomycin iFOSFamide) (part 2b of VIDE followed by VAC or VAI) High August 2023
Ewing sarcoma VDC (vinCRIStine, DOXOrubicin, CYCLOPHOSPHamide) (part 1 of VDC/IE) High August 2023
Ewing sarcoma VIDE (vinCRISTine iFOSFamide DOXOrubicin etoposide) (part 1 of VIDE followed by VAC or VAI) High August 2023
Giant cell tumour of bone denosumab Low August 2023
Osteosarcoma MAP (methotrexate, DOXOrubicin, cISplatin) Medium August 2023

Notes

  1. Permitted to be administered in low-risk units for second and subsequent cycles for patients with ECOG performance status 0 or 1 showing ≤ Grade 1 toxicity
  2. Fluorouracil pumps may be connected/disconnected at low-risk units
  3. Non-formulary drug included in the protocol
  4. Continuation dual treatment with pertuzumab and trastuzumab can be provided to appropriate patients at low-risk chemotherapy units.